LY3471851

DRUG9 trials

Sponsors

Nektar Therapeutics

Conditions

Colitis, UlcerativeDermatitis, AtopicHealthyPsoriasisSystemic Lupus Erythematosus

Phase 1

A Study of NKTR-358 (LY3471851) in Participants With Systemic Lupus Erythematosus (SLE)

CompletedNCT03556007

Nektar TherapeuticsSystemic Lupus Erythematosus

Start: 2018-04-18End: 2019-08-29Updated: 2023-11-18

A Study of LY3471851 in Participants With Eczema

CompletedNCT04081350

Nektar TherapeuticsDermatitis, Atopic

Start: 2019-12-04End: 2022-06-24Updated: 2024-02-20

A Study of LY3471851 in Participants With Psoriasis

CompletedNCT04119557

Nektar TherapeuticsPsoriasis

Start: 2019-11-26End: 2021-07-21Updated: 2024-02-20

A Study of LY3471851 in Healthy Participants

CompletedNCT04133116

Nektar TherapeuticsHealthy

Start: 2019-10-29End: 2020-03-06Updated: 2023-11-18

A Study of NKTR-358 (LY3471851) in Healthy Participants

CompletedNCT04380324

Nektar TherapeuticsHealthy

Start: 2017-03-19End: 2019-01-20Updated: 2023-11-18

A Single-Dose Study of LY3471851 in Healthy Participants

CompletedNCT04998487

Nektar TherapeuticsHealthy

Start: 2021-08-16End: 2022-07-06Updated: 2023-11-18

A Phase I Study of LY3471851 in Healthy Participants

CompletedNCT05565729

Nektar TherapeuticsHealthy

Start: 2022-10-05End: 2023-02-23Updated: 2023-11-18

Phase 2

A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE)

CompletedNCT04433585

Nektar TherapeuticsSystemic Lupus Erythematosus

Start: 2020-08-19End: 2023-02-16Updated: 2024-04-23

A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC)

TerminatedNCT04677179

Nektar TherapeuticsColitis, Ulcerative

Start: 2021-03-22End: 2022-08-09Updated: 2023-09-05

Related Papers

The regulatory T cell-selective interleukin-2 receptor agonist rezpegaldesleukin in the treatment of inflammatory skin diseases: two randomized, double-blind, placebo-controlled phase 1b trials.

2024-10-2516 citations

Recent patents in allergy and immunology: The interleukin‐2 receptor pathway agonist rezpegaldesleukin (REZPEG) for the rescue of regulatory T cells in chronic inflammatory and autoimmune diseases

Allergy2024-08-162 citations

Selective expansion of regulatory T cells by NKTR-358 in healthy volunteers and patients with systemic lupus erythematosus.

2022-03-2826 citations